Switch to:

GuruFocus Financial Strength Rank measures how strong a company’s financial situation is. It is based on these factors

1. The debt burden that the company has as measured by its Interest coverage (current year).
2. Debt to revenue ratio. The lower, the better
3. Altman Z-score.

A company ranks high with financial strength is likely to withstand any business slowdowns and recessions.

Financial Strength : 6/10

vs
industry
vs
history
Cash to Debt 0.77
ARAY's Cash to Debt is ranked higher than
60% of the 475 Companies
in the Global Medical Devices industry.

( Industry Median: 2.27 vs. ARAY: 0.77 )
ARAY' s 10-Year Cash to Debt Range
Min: 0.77   Max: No Debt
Current: 0.77

Equity to Asset 0.18
ARAY's Equity to Asset is ranked lower than
53% of the 453 Companies
in the Global Medical Devices industry.

( Industry Median: 0.64 vs. ARAY: 0.18 )
ARAY' s 10-Year Equity to Asset Range
Min: -0.65   Max: 0.69
Current: 0.18

-0.65
0.69
F-Score: 5
Z-Score: 0.74
M-Score: -2.80
GuruFocus Profitability Rank ranks how profitable a company is and how likely the company’s business will stay that way. It is based on these factors:

1. Operating Margin
2. Trend of the Operating Margin (5-year average). The company with an uptrend profit margin has a higher rank.
••3. Consistency of the profitability
4. Piotroski F-Score
5. Predictability Rank•

The maximum rank is 10. A rank of 7 or higher means a higher profitability and may stay that way. A rank of 3 or lower indicates that the company has had trouble to make a profit.

Profitability Rank is not directly related to the Financial Strength Rank. But if a company is consistently profitable, its financial strength will be stronger.

Profitability & Growth : 5/10

vs
industry
vs
history
Operating margin (%) -5.63
ARAY's Operating margin (%) is ranked higher than
62% of the 458 Companies
in the Global Medical Devices industry.

( Industry Median: 5.49 vs. ARAY: -5.63 )
ARAY' s 10-Year Operating margin (%) Range
Min: -586.2   Max: 1.28
Current: -5.63

-586.2
1.28
Net-margin (%) -11.08
ARAY's Net-margin (%) is ranked higher than
60% of the 458 Companies
in the Global Medical Devices industry.

( Industry Median: 3.95 vs. ARAY: -11.08 )
ARAY' s 10-Year Net-margin (%) Range
Min: -584.5   Max: 2.56
Current: -11.08

-584.5
2.56
ROE (%) -44.72
ARAY's ROE (%) is ranked higher than
53% of the 443 Companies
in the Global Medical Devices industry.

( Industry Median: 5.07 vs. ARAY: -44.72 )
ARAY' s 10-Year ROE (%) Range
Min: -68.25   Max: 4.2
Current: -44.72

-68.25
4.2
ROA (%) -8.64
ARAY's ROA (%) is ranked higher than
60% of the 475 Companies
in the Global Medical Devices industry.

( Industry Median: 2.61 vs. ARAY: -8.64 )
ARAY' s 10-Year ROA (%) Range
Min: -72.32   Max: 1.72
Current: -8.64

-72.32
1.72
ROC (Joel Greenblatt) (%) -45.57
ARAY's ROC (Joel Greenblatt) (%) is ranked higher than
60% of the 473 Companies
in the Global Medical Devices industry.

( Industry Median: 8.37 vs. ARAY: -45.57 )
ARAY' s 10-Year ROC (Joel Greenblatt) (%) Range
Min: -383.97   Max: 15.55
Current: -45.57

-383.97
15.55
Revenue Growth (%) 9.60
ARAY's Revenue Growth (%) is ranked higher than
83% of the 339 Companies
in the Global Medical Devices industry.

( Industry Median: 5.40 vs. ARAY: 9.60 )
ARAY' s 10-Year Revenue Growth (%) Range
Min: -7   Max: 133.5
Current: 9.6

-7
133.5
EPS Growth (%) 2.20
ARAY's EPS Growth (%) is ranked higher than
76% of the 297 Companies
in the Global Medical Devices industry.

( Industry Median: 2.20 vs. ARAY: 2.20 )
ARAY' s 10-Year EPS Growth (%) Range
Min: 2.2   Max: 91.3
Current: 2.2

2.2
91.3
» ARAY's 10-Y Financials

Financials


Revenue & Net Income
Cash & Debt
Oprt. Cash Flow & Free Cash Flow

» Details

Guru Trades

Q4 2013

ARAY Guru Trades in Q4 2013

Jim Simons 447,523 sh (New)
Steven Cohen 1,007,200 sh (+54.95%)
Chuck Royce 1,468,500 sh (+1.73%)
PRIMECAP Management 8,301,600 sh (unchged)
» More
Q1 2014

ARAY Guru Trades in Q1 2014

Chuck Royce 1,560,000 sh (+6.23%)
PRIMECAP Management 8,785,500 sh (+5.83%)
Steven Cohen 814,200 sh (-19.16%)
Jim Simons 247,640 sh (-44.66%)
» More
Q2 2014

ARAY Guru Trades in Q2 2014

Jim Simons 529,123 sh (+113.67%)
Chuck Royce 1,690,500 sh (+8.37%)
Steven Cohen 1,028,900 sh (unchged)
PRIMECAP Management 8,690,700 sh (-1.08%)
» More
Q3 2014

ARAY Guru Trades in Q3 2014

Paul Tudor Jones 36,179 sh (New)
Jim Simons 1,312,023 sh (+147.96%)
Steven Cohen 1,277,500 sh (+24.16%)
PRIMECAP Management 8,665,700 sh (-0.29%)
Chuck Royce 1,658,500 sh (-1.89%)
» More
» Details

Insider Trades

Latest Guru Trades with ARAY

(List those with share number changes of more than 20%, or impact to portfolio more than 0.1%)

GuruDate Trades Impact to Portfolio Price Range * (?) Current Price Change from Average Current Shares
John Burbank 2013-09-30 Sold Out 0.37%$5.41 - $7.3 $ 7.1113%0
John Burbank 2013-06-30 Reduce -51.5%0.38%$4.17 - $5.9 $ 7.1141%1940013
George Soros 2011-09-30 Sold Out 0.0018%$3.63 - $8.73 $ 7.1120%0
Jean-Marie Eveillard 2011-09-30 Sold Out 0.0011%$3.63 - $8.73 $ 7.1120%0
Premium More recent guru trades are included for Premium Members only!!
Premium More recent guru trades are included for USA Subscribe Members only!!
» Interactive Charts

Peter Lynch Chart ( What is Peter Lynch Charts )

Ratios

vs
industry
vs
history
P/B 6.85
ARAY's P/B is ranked higher than
57% of the 511 Companies
in the Global Medical Devices industry.

( Industry Median: 3.78 vs. ARAY: 6.85 )
ARAY' s 10-Year P/B Range
Min: 1.1   Max: 11.5
Current: 6.85

1.1
11.5
P/S 1.45
ARAY's P/S is ranked higher than
84% of the 511 Companies
in the Global Medical Devices industry.

( Industry Median: 3.40 vs. ARAY: 1.45 )
ARAY' s 10-Year P/S Range
Min: 0.81   Max: 5.99
Current: 1.45

0.81
5.99
EV-to-EBIT -28.35
ARAY's EV-to-EBIT is ranked higher than
62% of the 511 Companies
in the Global Medical Devices industry.

( Industry Median: 73.45 vs. ARAY: -28.35 )
ARAY' s 10-Year EV-to-EBIT Range
Min: -623.5   Max: 802.9
Current: -28.35

-623.5
802.9
Current Ratio 2.04
ARAY's Current Ratio is ranked higher than
63% of the 474 Companies
in the Global Medical Devices industry.

( Industry Median: 2.72 vs. ARAY: 2.04 )
ARAY' s 10-Year Current Ratio Range
Min: 0.92   Max: 3.13
Current: 2.04

0.92
3.13
Quick Ratio 1.43
ARAY's Quick Ratio is ranked higher than
63% of the 474 Companies
in the Global Medical Devices industry.

( Industry Median: 1.95 vs. ARAY: 1.43 )
ARAY' s 10-Year Quick Ratio Range
Min: 0.72   Max: 2.67
Current: 1.43

0.72
2.67

Valuation & Return

vs
industry
vs
history
Price/Tangible Book 712.00
ARAY's Price/Tangible Book is ranked higher than
55% of the 511 Companies
in the Global Medical Devices industry.

( Industry Median: 6.57 vs. ARAY: 712.00 )
ARAY' s 10-Year Price/Tangible Book Range
Min: 1.97   Max: 740
Current: 712

1.97
740
Price/Median PS Value 0.84
ARAY's Price/Median PS Value is ranked higher than
87% of the 511 Companies
in the Global Medical Devices industry.

( Industry Median: 1.21 vs. ARAY: 0.84 )
ARAY' s 10-Year Price/Median PS Value Range
Min: 0.48   Max: 3.21
Current: 0.84

0.48
3.21
Earnings Yield (Greenblatt) -3.50
ARAY's Earnings Yield (Greenblatt) is ranked higher than
61% of the 464 Companies
in the Global Medical Devices industry.

( Industry Median: 2.40 vs. ARAY: -3.50 )
ARAY' s 10-Year Earnings Yield (Greenblatt) Range
Min: 0.1   Max: 2.9
Current: -3.5

0.1
2.9
Forward Rate of Return (Yacktman) -3.18
ARAY's Forward Rate of Return (Yacktman) is ranked higher than
68% of the 349 Companies
in the Global Medical Devices industry.

( Industry Median: 0.59 vs. ARAY: -3.18 )
ARAY' s 10-Year Forward Rate of Return (Yacktman) Range
Min: -4.4   Max: 3.9
Current: -3.18

-4.4
3.9

Business Description

Industry: Medical Devices » Medical Devices
Compare:MDT, SYK, SMA, ZMH, STJ » details
Traded in other countries:XEJ.Germany
Accuray Inc was incorporated in California in 1990 and commenced operations in 1992. The Company was reincorporated in 2007 in Delaware. The Company is a radiation oncology company. The Company's technologies are designed specifically to deliver precise radiosurgery, stereotactic body radiation therapy, intensity modulated radiation therapy, and image guided radiation therapy and adaptive radiation therapy tailored to the specific needs of each patient. Its suite of products includes the CyberKnife Systems and the TomoTherapy Systems. The CyberKnife Systems are fully robotic stereotactic radiosurgery systems, or SRS and stereotactic body radiation therapy systems, or SBRT used to treat multiple types of cancer and tumors throughout the body. The CyberKnife Systems automatically track, detect and correct for tumor and patient movement in real-time during the procedure, enabling delivery of precise, high dose radiation with sub-millimeter accuracy while patients breathe normally. Treatment with the CyberKnife Systems requires no anesthesia, and can be performed in one to five staged treatment sessions on an outpatient basis. In addition, the CyberKnife Systems are designed to minimize many of the risks and complications that are associated with other treatment options. The CyberKnife Systems include: the CyberKnife G4, which includes the Fixed collimator; CyberKnife VSI System, which includes the Fixed and Iris collimators and the new CyberKnife M6 Series System, that comes in configurations that have the option of Fixed collimator, Iris collimator, and a MultiLeaf collimator, or MLC. The TomoTherapy Systems are used to treat a wide range of cancers and tumors, and enable efficient daily imaging to ensure the accuracy of the patient position before each treatment delivery. The TomoTherapy Systems operate on ring gantries and combine integrated CT imaging with intensity modulated radiation therapy or IMRT, which is designed to deliver radiation treatments with speed and precision while reducing radiation exposure to surrounding healthy tissue. The TomoTherapy Systems include the Hi-Art System, delivering CT-guided, helical IMRT; the TomoHD System, which includes both the TomoHelicalTM and TomoDirectTM treatment modalities and the Tomo H TM Series Systems that come in configuration options of TomoHTM, TomoHD and TomoHDATM and which includes one or more options such as TomoHelicalTM, TomoDirectTM, High Performance VoLo TM Planning and TomoEdge Dynamic Jaws.
» More Articles for ARAY

Headlines

Articles On GuruFocus.com
Weekly CEO Buys Highlight: SONS, OPK, AKS, ARAY, ENH Nov 09 2014 
Weekly CEO Buys Highlight: JMP, SONS, OPK, ARAY, CBNJ Nov 04 2014 
Accuray: Leading the Field Of Radiosurgery Jul 24 2014 
comment on ARAY May 12 2013 
comment on ARAY May 10 2013 
comment on ARAY May 10 2013 
comment on ARAY May 10 2013 
Weekly CEO Buys Highlight: AGNC, WTSLA, ARAY, FSC, SREV Feb 19 2013 
Weekly CFO Buys Highlight: POL, ARAY, ZBB, CRMD, VRX Dec 19 2011 
Accuray Inc. (ARAY) President & CEO Euan Thomson sells 12,500 Shares Mar 11 2011 


More From Other Websites
Nasdaq stocks posting largest percentage decreases Nov 25 2014
ACCURAY INC Files SEC form 8-K, Submission of Matters to a Vote of Security Holders Nov 20 2014
Accuray CyberKnife M6 System Now Available in Manhattan Nov 19 2014
First CyberKnife® Full-Body Radiosurgery System in Manhattan Now Treating Patients Nov 18 2014
ACCURAY INC Financials Nov 14 2014
ACCURAY INC Files SEC form 8-K, Other Events Nov 13 2014
Prostate Cancer Advertising: Lies And The Damn Lies (Part 1) Nov 10 2014
Accuray to Participate in Brean Capital's 2014 Life Science Conference Nov 10 2014
Accuray to Participate in Brean Capital's 2014 Life Science Conference Nov 10 2014
10-Q for Accuray, Inc. Nov 09 2014
ACCURAY INC Files SEC form 10-Q, Quarterly Report Nov 07 2014
Accuray (ARAY) Q1 Loss Wider Than Expected, Revenues Lag Nov 03 2014
Accuray (ARAY) Stock Lower Today After Earnings Miss Oct 30 2014
Accuray misses Street 1Q forecasts Oct 30 2014
Accuray misses Street 1Q forecasts Oct 30 2014
Accuray Inc Earnings Call scheduled for 4:30 pm ET today Oct 29 2014
Accuray Reports Financial Results for First Quarter of Fiscal Year 2015 Oct 29 2014
ACCURAY INC Files SEC form 8-K, Results of Operations and Financial Condition, Financial Statements... Oct 29 2014
Accuray Reports Financial Results for First Quarter of Fiscal Year 2015 Oct 29 2014
Q1 2015 Accuray Inc Earnings Release - After Market Close Oct 29 2014

Personalized Checklist

Checklist has been moved to "Checklist" tab.

Get WordPress Plugins for easy affiliate links on Stock Tickers and Guru Names | Earn affiliate commissions by embedding GuruFocus Charts
GuruFocus Affiliate Program: Earn up to $400 per referral. ( Learn More)
Free 7-day Trial
FEEDBACK